{"entity":{"id":"nct04404595","kind":"trial","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","aka":[],"tldr":"A phase 1/2 trial of CT041 in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.","summary":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers is a phase 1/2 interventional study registered as NCT04404595 by CARsgen Therapeutics Co., Ltd., with 110 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2025-06-01. Interventions recorded: CT041.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04404595","url":"https://clinicaltrials.gov/study/NCT04404595"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["carsgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04404595","phase":"1/2","setting":"Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers","sponsor":"CARsgen Therapeutics Co., Ltd.","enrolled":110,"outcomes":[]},"route":"/trials/nct04404595/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"}]}}